摘要
目的比较链脲菌素联合氟尿嘧啶与链脲菌素联合多柔比星治疗胰岛细胞癌的疗效。方法选取2006年1月至2016年12月就诊的90例胰岛细胞癌患者。采用随机数字法将患者分为链脲菌素+氟尿嘧啶组(采用链脲菌素+氟尿嘧啶静脉滴注,每6周为1个治疗周期)和链脲菌素+多柔比星组(采用链脲菌素+多柔比星静脉滴注,每6周为1个治疗周期)。治疗6个周期后,分别进行观察和随访,比较两组患者肿瘤大小变化、生存时间及药物治疗相关的不良反应。结果经随访(22.96±3.68)个月,失访10例,获随访的80例中链脲菌素+氟尿嘧啶组42例,链脲菌素+多柔比星组38例。治疗后,链脲菌素+氟尿嘧啶组42例中肿瘤增大者12例(28.57%)、缩小者21例(50.00%)、体积无变化者9例(21.43%);链脲菌素+多柔比星组38例中肿瘤增大者9例(23.68%)、缩小者25例(65.79%)、体积无变化者4例(10.53%);后者肿瘤缩小比例稍优于前者,但差异无统计学意义(Z=0.342,P=0.732)。获随访的80例患者总体中位生存期为19.6个月,链脲菌素+多柔比星组生存期(25.3±14.8)个月,优于链脲菌素+氟尿嘧啶组(15.9±11.6)个月(P<0.05)。链脲菌素+氟尿嘧啶组:8例患者出现重度血液系统并发症,4例致命性血液系统不良反应。链脲菌素+多柔比星组:13例患者出现重度血液系统并发症,3例致命性血液系统不良反应。结论在胰岛细胞癌治疗中,链脲菌素加多柔比星方案比链脲菌素加氟尿嘧啶的现行标准方案,更利于提高患者生存期。
Objective To compare the efficacy of streptozocin combined with fluorouracil and streptozocin combined with doxorubicin for the treatment of islet cell carcinoma. Methods A total of 90 patients with islet cell carcinoma who visited Xiangyang Central Hospital between January 2006 and December 2016 were selected. The patients were divided into streptozocin plus fluorouracil group （intravenous drip of streptozotoein and fluorouracil, one treatment cycle was 6 weeks ） and streptozocin plus doxorubicin group （intravenous drip of streptozotocin and doxorubicin, one treatment cycle was 6 weeks）according to the method of random number table. After treatment for 6 cycles, observation and follow up were performed to compare tumor size changes, survival time of patients and the adverse reactions associated with drug therapy between two groups. Results After follow-up of （22.96 ± 3.68 ） months, 10 cases were lost. Out of 80 cases of followed- up,42 cases were in streptozocin plus fluorouracil group, and 38 cases were in streptozocin plus doxorubicin group. There were 12 cases （ 28.57% ） of tumor volume enlargement, 21 cases （ 50. 00% ） of tumor volume shrinking and 9 cases （21.43%）of tumor volume without change after treatment in streptozocin plus fluorouracil group. There were 9 cases （23.68%） of tumor volume enlargement,25 cases （23.68%） of tumor volume shrinking and 4 cases （ 10. 53% ） of tumor volume without change after treatment in streptozocin plus doxorubicin group. The tumor shrinking ratio in streptozocin plus doxorubicin group was slightly better than that in streptozocin plus fluorouraeil group, but the difference had not statistical significance（z = 0. 342 ,P =0. 732 ）. The overall median survival time was 19. 6 months in 80 cases of followed-up. The survival time in streptozocin plus doxorubicin group was batter than that in streptozocin plus fluorouracil group [ （25.3 ±14. 8 ） months vs （ 15.9 ± 11.6 ） months, P 〈 0. 05 ]. In streptozocin plus fluorouracil g
出处
《中国临床研究》
CAS
2018年第1期32-35,共4页
Chinese Journal of Clinical Research
基金
国家自然科学基金委员会(81601373)
